Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report By Product (Gene Therapy, Cell Therapy), By Phase, By Indication, By Region, And Segment Forecasts, 2024 - 2030

Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report By Product (Gene Therapy, Cell Therapy), By Phase, By Indication, By Region, And Segment Forecasts, 2024 - 2030


Advanced Therapy Medicinal Products CDMO Market Growth & Trends

The global advanced therapy medicinal products CDMO market size is expected to reach USD 18.8 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 18.92% from 2024 to 2030, owing to rising clinical trials for advanced therapy medicinal products and the increasing awareness among researchers about the benefits of advanced therapies, driving the advanced therapy medicinal products (ATMP) CDMO market growth. Tissue engineering has greatly benefited in recent years from technological development. The damaged tissues and organ function are replaced or restored using this technique. Similarly, gene and cell therapy are attracting a lot of patients for the treatment of rare diseases, whose incidence is rising globally.

With rising demand for robust disease treatment therapies, key players have focused their efforts to ramp up research and development for effective gene therapies that target the cause of disorder at a genomic level. According to ASGCT, the number of cell and gene therapies in the U.S. pipeline programs (phase I-III trials) increased from 483 in 2021 to 529 in 2022. Furthermore, the FDA delivers constant support for innovations in the gene therapy field via a number of policies with regard to product manufacturing. In January 2020, the agency released six final guidelines on the manufacturing and clinical development of safe & efficient gene therapy products.

Moreover, awareness about ATMP treatment options is being driven by initiatives aimed at informing the public about the benefits of these products, which, in turn, is leading to increased adoption of advanced therapies and fueling market growth for CDMOs. For instance, Alliance for Regenerative Medicine Foundation for Cell and Gene Medicine prioritizes activities for increasing public awareness through educational programs, underlining the clinical & societal benefits of regenerative medicine.

Increasing clinical trial activity along with new product launches generates growth opportunities for the market. As of 2022, there are 1451 ATMPs in preclinical stages and 535 are being studied in Phase 1 to 3 studies. Since August 2020, EMA has approved six of these additional ATMPs, and five more will be approved by 2023. In the UK, there were approximately 168 advanced therapy medicinal product trials underway in 2021, up from the 154 studies reported the year before, which is a 9% increase. 2021 saw a 32% increase in phase 1 trials, indicating a significant shift from experimental medicines to first-in-human studies.

On the other hand, key players are undertaking various strategic initiatives to introduce novel products, which is expected to propel market growth. For instance, in March 2021, CureVac N.V. signed a partnership agreement with Celonic Group, engaged in the manufacture of CVnCoV, CureVac’s mRNA-based COVID-19 vaccine candidate. CureVac's COVID-19 vaccine candidate is manufactured at Celonic's commercial manufacturing unit for ATMPs and biologics in Heidelberg, Germany. Under the terms of the commercial supply agreement, the Celonic facility could produce over 100 million doses of CVnCoV.

Advanced Therapy Medicinal Products CDMO Market Report Highlights
  • The gene therapy segment held the largest share of over 49.2% in 2023. Increase in financial support and rise in number of clinical trials for gene therapies are driving demand for the gene therapy segment.
  • The cell therapy segment is expected to show lucrative growth over the forecast period. The field of cellular therapeutics is constantly advancing with inclusion of new cell types, which, in turn, provides ample opportunities for companies to enhance their market positions.
  • The oncology segment accounted for the largest revenue share in 2023. The segment’s dominance is attributed to disease burden, strategic initiatives undertaken by key players, and availability of advanced therapies used for treating various cancer indications.
  • The phase I segment dominated the market in 2023 due to growing R&D activities and increasing number of human trials for advanced therapies.
  • North America dominated the overall market share of 49.0% in 2023. This can be attributed to increasing outsourcing activities and rising awareness about advanced therapy.
  • The Asia Pacific region is expected to grow at the fastest CAGR over the forecast period due to the increasing demand for novel ATMPs and rising R&D activities to develop novel therapies.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology And Scope
1.1. Market Segmentation And Scope
1.1.1. Segment Definitions
1.1.1.1. Product Segment
1.1.1.2. Phase Segment
1.1.1.3. Indication Segment
1.2. Regional Scope
1.3. Estimates And Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List Of Primary Sources
1.11. List Of Abbreviations
Chapter 2. Advanced Therapy Medicinal Products CDMO Market: Executive Summary
2.1. Market Snapshot
2.2. Products Snapshots
2.3. Phase Snapshots
2.4. Indication Snapshot
2.5. Competitive Landscape Snapshot
Chapter 3. Advanced Therapy Medicinal Products CDMO Market Variables, Trends, & Scope
3.1. Market Segmentation And Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Rising number of clinical trials for ATMPs
3.4.2. Increasing outsourcing activities
3.4.3. Growing awareness of the treatment
3.5. Market Restraint Analysis
3.5.1. Stringent regulatory approvals
3.5.2. High cost of outsourcing
3.6. Advanced Therapy Medicinal Products CDMO Market Analysis Tools
3.6.1. Industry Analysis - Porter’s
3.6.1.1. Supplier Power
3.6.1.2. Buyer Power
3.6.1.3. Substitution Threat
3.6.1.4. Threat Of New Entrant
3.6.1.5. Competitive Rivalry
3.6.2. PESTLE Analysis
3.6.2.1. Political Landscape
3.6.2.2. Technological Landscape
3.6.2.3. Economic Landscape
Chapter 4. Advanced Therapy Medicinal Products CDMO: Products Estimates & Trend Analysis
4.1. Product Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Advanced Therapy Medicinal Products CDMO Market, By Product Outlook
4.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
4.4.1. Gene Therapy
4.4.1.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
4.4.2. Cell Therapy
4.4.2.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
4.4.3. Tissue Engineered
4.4.3.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
4.4.4. Others
4.4.4.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
Chapter 5. Advanced Therapy Medicinal Products CDMO: Phase Estimates & Trend Analysis
5.1. Phase Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Advanced Therapy Medicinal Products CDMO Market, By Phase Outlook
5.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
5.4.1. Phase I
5.4.1.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
5.4.2. Phase II
5.4.2.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
5.4.3. Phase III
5.4.3.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
5.4.4. Phase IV
5.4.4.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
Chapter 6. Advanced Therapy Medicinal Products CDMO: Indication Estimates & Trend Analysis
6.1. Indication Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Advanced Therapy Medicinal Products CDMO Market, By Indication Outlook
6.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
6.4.1. Oncology
6.4.1.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.2. Cardiology
6.4.2.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.3. Central Nervous System
6.4.3.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.4. Musculoskeletal
6.4.4.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.5. Infectious Disease
6.4.5.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.6. Dermatology
6.4.6.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.7. Endocrine, Metabolic, Genetic
6.4.7.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.8. Immunology & Inflammation
6.4.8.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.9. Ophthalmology
6.4.9.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.10. Hematology
6.4.10.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.11. Gastroenterology
6.4.11.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
6.4.12. Others
6.4.12.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Marker Size, & Forecasts Trend Analysis, 2018 To 2030:
7.5. North America
7.5.1. U.S.
7.5.1.1. Key Country Dynamics
7.5.1.2. Competitive Scenario
7.5.1.3. Regulatory Framework
7.5.1.4. U.S. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.5.2. Canada
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Canada Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.6. Europe
7.6.1. UK
7.6.1.1. Key Country Dynamics
7.6.1.2. Competitive Scenario
7.6.1.3. Regulatory Framework
7.6.1.4. UK Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.6.2. Germany
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. Germany Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.6.3. Spain
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. Spain Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.6.4. France
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. France Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.6.5. Italy
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Italy Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.6.6. Denmark
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Framework
7.6.6.4. Denmark Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.6.7. Sweden
7.6.7.1. Key Country Dynamics
7.6.7.2. Competitive Scenario
7.6.7.3. Regulatory Framework
7.6.7.4. Sweden Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.6.8. Norway
7.6.8.1. Key Country Dynamics
7.6.8.2. Competitive Scenario
7.6.8.3. Regulatory Framework
7.6.8.4. Norway Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.7. Asia Pacific
7.7.1. Japan
7.7.1.1. Key Country Dynamics
7.7.1.2. Competitive Scenario
7.7.1.3. Regulatory Framework
7.7.1.4. Japan Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.7.2. China
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Framework
7.7.2.4. China Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.7.3. India
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Framework
7.7.3.4. India Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.7.4. South Korea
7.7.4.1. Key Country Dynamics
7.7.4.2. Competitive Scenario
7.7.4.3. Regulatory Framework
7.7.4.4. South Korea Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.7.5. Thailand
7.7.5.1. Key Country Dynamics
7.7.5.2. Competitive Scenario
7.7.5.3. Regulatory Framework
7.7.5.4. Thailand Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.7.6. Australia
7.7.6.1. Key Country Dynamics
7.7.6.2. Competitive Scenario
7.7.6.3. Regulatory Framework
7.7.6.4. Australia Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.8. Latin America
7.8.1. Brazil
7.8.1.1. Key Country Dynamics
7.8.1.2. Competitive Scenario
7.8.1.3. Regulatory Framework
7.8.1.4. Brazil Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.8.2. Mexico
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Framework
7.8.2.4. Mexico Advanced Therapy Medicinal Products CDMO Market, 2018 - 2030 (USD Million)
7.8.3. Argentina
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Framework
7.8.3.4. Argentina Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.9. MEA
7.9.1. MEA Advanced Therapy Medicinal Products CDMO Market, 2018 - 2030 (USD Million)
7.9.2. South Africa
7.9.2.1. Key Country Dynamics
7.9.2.2. Competitive Scenario
7.9.2.3. Regulatory Framework
7.9.2.4. South Africa Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.9.3. Saudi Arabia
7.9.3.1. Key Country Dynamics
7.9.3.2. Competitive Scenario
7.9.3.3. Regulatory Framework
7.9.3.4. Saudi Arabia Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.9.4. UAE
7.9.4.1. Key Country Dynamics
7.9.4.2. Competitive Scenario
7.9.4.3. Regulatory Framework
7.9.4.4. UAE Market Estimates And Forecasts, 2018 To 2030 (USD Million)
7.9.5. Kuwait
7.9.5.1. Key Country Dynamics
7.9.5.2. Competitive Scenario
7.9.5.3. Regulatory Framework
7.9.5.4. Kuwait Market Estimates And Forecasts, 2018 To 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company /Competition Categorization
8.3. Vendor Landscape
8.3.1. List Of Key Distributors And Channel Partners
8.3.2. Key Customers
8.3.3. Key Company Market Share Analysis, 2023
8.3.4. CELONIC Group
8.3.4.1. Overview
8.3.4.2. Financial Performance
8.3.4.3. Product Benchmarking
8.3.4.4. Strategic Initiatives
8.3.5. Bio Elpida
8.3.5.1. Overview
8.3.5.2. Financial Performance
8.3.5.3. Product Benchmarking
8.3.5.4. Strategic Initiatives
8.3.6. Rentschler Biopharma SE
8.3.6.1. Overview
8.3.6.2. Financial Performance
8.3.6.3. Product Benchmarking
8.3.6.4. Strategic Initiatives
8.3.7. AGC Biologics
8.3.7.1. Overview
8.3.7.2. Financial Performance
8.3.7.3. Product Benchmarking
8.3.7.4. Strategic Initiatives
8.3.8. Catalent, Inc.
8.3.8.1. Overview
8.3.8.2. Financial Performance
8.3.8.3. Product Benchmarking
8.3.8.4. Strategic Initiatives
8.3.9. Lonza
8.3.9.1. Overview
8.3.9.2. Financial Performance
8.3.9.3. Product Benchmarking
8.3.9.4. Strategic Initiatives
8.3.10. Wuxi Advanced Therapies
8.3.10.1. Overview
8.3.10.2. Financial Performance
8.3.10.3. Product Benchmarking
8.3.10.4. Strategic Initiatives
8.3.11. Minaris Regenerative Medicine
8.3.11.1. Overview
8.3.11.2. Financial Performance
8.3.11.3. Product Benchmarking
8.3.11.4. Strategic Initiatives
8.3.12. Patheon, Inc.
8.3.12.1. Overview
8.3.12.2. Financial Performance
8.3.12.3. Product Benchmarking
8.3.12.4. Strategic Initiatives
8.3.13. CGT Catapult
8.3.13.1. Overview
8.3.13.2. Financial Performance
8.3.13.3. Product Benchmarking
8.3.13.4. Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings